COVID-19 Protein Found to Speed Toxic Alpha-Synuclein Buildup
A protein present in the SARS-CoV-2 virus — the virus that causes COVID-19 — is able to interact with alpha-synuclein…
Articles by Patricia Inácio, PhD
Age-related Eye Disease Heightens Parkinson’s Risk, Study Suggests
People with age-related macular degeneration, an eye disease that blurs central vision, may have a higher risk of developing…
Tweaked Peptide May Prevent Toxic Alpha-synuclein Clumps From Forming
A new molecule — a peptide tweaked by scientists in the laboratory — has the potential to prevent the misfolding…
Low Oxygen Levels, Poor Exercise Endurance Are Common
Low oxygen levels during sleep and while exercising — resulting in poor endurance — are very common among Parkinson’s…
Damage to Blood Vessels of Brain May Drive Parkinson’s Progression
The cerebrospinal fluid, which surrounds the brain and spinal cord, of people with moderately severe Parkinson’s disease shows evidence…
Supernus Boosts Therapy Portfolio With Finalized Buyout of Adamas
Supernus Pharmaceuticals’ portfolio of Parkinson’s disease therapies now includes Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride), with the company’s…
Cala Health Raises $77M for Bioelectronic Devices for Tremors
Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine —…
1st Trial of Anesthetic Ketamine for Depression in Parkinson’s Wins $2M
Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first…
STAR Molecule to Restore GCase Activity Showing Early Potential
An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits…
Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy
Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a…